Test Results For:

Vitamin D (25(OH))

Test Name

Vitamin D (25(OH))

Test Code
VITD

Short Description

Vit D

Test Name

Vitamin D (25(OH))

Test Code

VITD

Category

Immunoassay

TAT

Main Lab: 6, Hour(s)
Family Site: <6hrs, <8hrs

Specimen(s)

1 x Venous blood - 5 mL Tube - Gold - SST-Serum Separator Tube

Specimen Type

SST-Serum Separator Tube

Specimen Format

Tube

Specimen Colour

Gold

Specimen Volume

5 mL

Sampling Order

2

Origin

Venous blood

Collection Time after baseline

-

Transport Temperature

2-8°C

Accepted Other Specimens

Serum

TAT

Main Lab: 6, Hour(s)
Family Site: <6hrs, <8hrs

Test Stability

Room Temp: 3 Hour(s)
2–8°C: 6 Hour(s)

Methodology

-

Specimen Type

SST-Serum Separator Tube

Other Type of Specimen Accepted

Serum

Delay before pre-treatment

3

Transport temperature

2-8°C

Test stability at room temperature

3 Hour(s)

Test stability at 2–8°C

6 Hour(s)

Haemolysis interference

No


Clinical Interest

The measurement of 25-hydroxyvitamin D (25 (OH)D) is indicated to confirm deficiency in cases of musculoskeletal symptoms (bone pain, muscle weakness, atypical fractures, rickets, or osteomalacia), or in at-risk populations: elderly individuals, people with pigmented skin, low sun exposure, obesity (BMI > 30), malabsorption (celiac disease, IBD), chronic renal or hepatic failure, pregnant or breastfeeding women.


It is routinely performed as part of osteoporosis screening, particularly in cases of fragility fractures or before starting anti-osteoporotic treatment. It also helps distinguish between secondary hyperparathyroidism (related to vitamin D3 deficiency, with high PTH and low 25(OH)D) and primary hyperparathyroidism. Finally, it is used for therapeutic monitoring during supplementation, especially at high doses, or in patients receiving interfering treatments (antiepileptics, glucocorticoids, antiretrovirals).


The interpretation thresholds used are:

  • deficiency (< 20 ng/mL or < 50 nmol/L), insufficiency (20–29 ng/mL or 50–74 nmol/L),
  • and a therapeutic target between 30 and 50 ng/mL (75–125 nmol/L).

A level above 100 ng/mL (> 250 nmol/L) exposes the patient to a risk of hypercalcemia.

Clinical Information Required

-


Patient Collection Note

-

LOINC Code

89-3, 1989-3,

Outwork

No

Notification just now
URL copied to clipboard.
Find a Lab Now

Cerba Lancet Africa on the continent

Botswana Eswatini Ethiopia Gabon Ghana Ivory Coast Kenya Mozambique Nigeria Rwanda Tanzania Uganda Zambia Zimbabwe